BFRI

Biofrontera Inc.

$0.93

4.56%
SectorHealthcareIndustryDrug Manufacturers - Specialty & GenericCountryUnited States

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Source: Yahoo Finance
AI summary

Price & performance

1M-39.1%
3M-23.4%
YTD+10.9%
1Y-18.8%
52-week range—
Beta0.87
Full chart and returns against a benchmark

Q-Score

39/ 100

Quality against peers; 50 is the peer median.

Growth58
Risk39
Performance36
Valuation51
Profitability30
Leverage42
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$41.7M+11.7%
Net income-$10.5M
Net margin-25.3%+22.3 pts
Historical fundamentals

Red flags in filings

3active red flags
Going-concern doubtMar 19, 2026
Auditor changeApr 18, 2025
Exchange listing noticeJan 7, 2026
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Regions, segments, customers and suppliers

Valuation

BFRIIndustryP/E—35.25P/S0.302.74EV/EBITDA—16.35P/B2.312.46PEG—0.87
Dividend yield0.00%
Every valuation metric

Earnings

Nov 13next report, before the open
EPS estimate$-0.11
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate